NUWE NUWELLIS INC

Nuwellis, Inc. Participates in a Virtual Investor “What This Means” Segment

Nuwellis, Inc. Participates in a Virtual Investor “What This Means” Segment

Watch the “What This Means” segment

MINNEAPOLIS, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company delivering fluid management solutions for critically ill patients, today announced that it participated in a . 

For the segment, of Nuwellis, discussed the Company’s recent news release announcing that the National Institutes of Health (NIH) has awarded an approximately $3 million multi-year grant to its development partner, Koronis Biomedical Technologies Corporation (KBT). The NIH-supported program will accelerate Vivian™, Nuwellis’ dedicated pediatric continuous renal replacement therapy (CRRT) device in development for patients under 20 kilograms, and advance core software and firmware that strengthen the company’s broader portfolio.

The Virtual Investor “What this Means” segment featuring Nuwellis is now available . 

About Nuwellis

Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit or visit us on LinkedIn or X, formerly known as Twitter.

For further information, please contact:

Investor Contact:

JTC Team, LLC

Jenene Thomas

(908) 824-0775

Media Contact:

Leah McMullen

Director of Communications



EN
17/09/2025

Underlying

NUWENUWELLIS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NUWELLIS INC

 PRESS RELEASE
Free
NUWE NUWELLIS INC

Nuwellis Pediatric Category Achieves Approximately 50% of Total U.S. R...

Nuwellis Pediatric Category Achieves Approximately 50% of Total U.S. Revenue in 2025, Marking Growth Milestone Pediatric footprint expands to 47 centers nationwide, including six of the nation’s top 10 children’s hospitals MINNEAPOLIS, March 31, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces continued momentum in its pediatric category, which is now the Company’s largest and fastest-growing category and represents approximately 50% of total U.S. revenue. “Our pedi...

15h / 24m 1 EN
 PRESS RELEASE
Free
NUWE NUWELLIS INC

Nuwellis Completes Acquisition of Rendiatech

Nuwellis Completes Acquisition of Rendiatech Adds automated kidney function monitoring technology to support earlier clinical insight and strengthen Nuwellis’ fluid management platform MINNEAPOLIS, March 17, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the completion of its previously announced acquisition of Rendiatech, Inc., an Israeli-based developer of automated kidney function monitoring technology designed to support clinical decision-making in critic...

March 17, 2026 1 EN
 PRESS RELEASE
Free
NUWE NUWELLIS INC

Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial R...

Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Recent Highlights: Fourth quarter revenue of $2.4 million, a 4% increase compared to the prior-year quarter and 9% increase sequentially.208% increase in U.S. console sales in Q4 versus prior year quarter.Heart Fa...

March 10, 2026 1 EN
 PRESS RELEASE
Free
NUWE NUWELLIS INC

Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Stra...

Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy Appointment Strengthens Clinical Leadership in Precision Fluid Management and Acute Kidney Injury MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Stuart L. Goldstein, MD, FASN as Director of Clinical Strategy. Dr. Goldstein is internationally recognized as a pioneer in pediatric nephrology and criti...

March 5, 2026 1 EN
 PRESS RELEASE
Free
NUWE NUWELLIS INC

Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of ...

Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company’s board with complementary expertise in public company leadership, capital markets, and medical device commercialization. “These appointments reflect our c...

February 26, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch